Federal Circuit Scrutinizes “Catch-and-Kill” Allegations in Pharma Merger Dispute
A recent hearing at the Federal Circuit has spotlighted a legal confrontation involving a medical training startup and Galderma, a pharmaceutical company. The startup accuses Galderma of employing a “classic catch-and-kill strategy” to sabotage a prospective $100 million deal with Allergan. The details emerged as the startup pushed for the revival of claims linked to…